JAMA Cardiol 2(12):13151321 Arnold SV, Stone GW, Mack MJ, Chhatriwalla AK, Austin BA, Zhang Z et al (2020) Health status changes and outcomes in patients with heart failure and mitral regurgitation: COAPT Trial
Tirzepatide is the first dual GLP-1 and GIP receptor agonist - it activates both the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide pathways simultaneously
Please check with your local customs office, as additional information may be required for clearance at this time
Sources: Teichman et al., JCEM 2006 | Raun et al., Eur J Endocrinol 1998 | Alba et al., Am J Physiol 2006 Security Profile & Chemical Identity Molecular specifications of the two peptides and documented hormonal selectivity Chemical Identity Pre-formulated Mix Two complementary peptides targeting distinct receptors for synergistic GH stimulation Documented Hormonal Selectivity Profile verified in human clinical trials Key benefit of this combination Published Clinical Data Key studies on each component and the synergy of GHRH + GHRP 2-10x Dose-dependent increase in plasma GH (30-60 g/kg SC) Results CJC-1295 (days 28 and 49) Selective First GH secretagogue without raising cortisol, prolactin or ACTH levels Selectivity vs
Which pharmacy compounds the medication, and what their plan is if the FDA finalizes the 503B exclusion
Tirzepatide has a high bioavailability of 81% and a half-life of 117 hours, allowing for convenient once-weekly dosing
